Drugdocs | Alunbrig

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Alunbrig

Chemical Name	brigatinib
Dosage Form	Tablet (oral; 30 mg, 90 mg, 180 mg)
Drug Class	Kinase inhibitors
System	Respiratory
Company	Takeda Pharmaceutical Company Limited
Approval Year	2017

Indication

For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Alunbrig (Brigatinib) Prescribing Information	2020	Takeda Pharmaceutical Company Limited, Cambridge, MA

Document Title	Year	Source
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib.	2019	NICE

Document Title	Year	Source
Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: A systematic review and network meta-analysis.	2020	Cancers (Basel)
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.	2018	Oncotarget

Document Title	Year	Source
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).	2018	Clinical and Translational Oncology
NCCN guidelines insights: Non–small cell lung cancer, version 5.2018.	2018	Journal of the National Comprehensive Cancer Network